Peptide payment processing

Why does peptide payment processing get flagged?

Peptide sellers get declined for a mix of reasons that have nothing to do with whether the products themselves are lawful to sell. Most peptides in this space are labelled for research use, sold to buyers who are not supposed to use them on themselves. Underwriters know that a meaningful share of research-use buyers plan to use the product on their own body anyway, and that gap between the label and the real-world use is exactly what worries a processor.

On top of that, the category carries genuinely high chargeback and reship rates. Product arrives late, arrives in the wrong dose, or the buyer disputes a charge after deciding the product did not do what a forum post promised. None of that is unique to peptides, but it shows up here more often than in most retail categories, and acquirers price and underwrite for the pattern they actually see.

Three dispute types drive most of the volume in this category, and each one maps to a specific operational gap:

• Non-delivery and reship disputes. Peptides often ship cold-chain, from a domestic supplier or an international one, and a delay in either leg (customs holds, courier mishandling, a lapsed cold pack) turns into a dispute the moment the buyer decides the wait is too long. This is the single biggest source of chargebacks in the category, and it is almost entirely a fulfillment problem, not a payments problem.
• "Not as described" disputes tied to purity or sourcing. A buyer who suspects the product is under-dosed, cut, or sourced from a different supplier than advertised files a dispute instead of asking for a refund first. This is where lab testing documentation matters, since it is the difference between a dispute the merchant can contest with paperwork and one it has no answer for.
• Refund pressure that becomes a chargeback anyway. A buyer asks for a refund, the merchant is slow or unclear about the process, and the buyer disputes the charge with their card issuer instead of waiting. A refund policy that exists on paper but is not followed in practice produces this pattern reliably.

None of these three are about whether the product is lawful. They are about whether the operation behind the product, sourcing, shipping, and refunds, is tight enough that a buyer never has a reason to go to their bank instead of the merchant.

What does a peptide business need to show an underwriter?

The application that moves is the one that treats the research-use label as a real operating boundary, not a legal formality printed on the box.

• Website copy that matches the label. If the site says "research use only," nothing else on the page should describe dosing for a person, a dosing schedule, or a health outcome.
• A clear order and fulfillment process. How the product ships, how fast, and what happens when a package is delayed or lost, since that is where a large share of disputes originate.
• A refund and return policy that is actually published, not just implied, so a dissatisfied buyer has a documented path other than a chargeback.
• Supplier and sourcing documentation. Where the product comes from and what testing or documentation exists behind it.
• A chargeback history the business can explain. Prior disputes are not disqualifying by themselves, what matters is whether the business can show what changed since.

This is the same posture that matters across high risk merchant processing generally: an acquirer that specializes in the category reviews the actual business, not just the SIC code, and wants to see that the operator understands its own exposure.

Beyond the standard business file (formation documents, a business bank account with real history, a processing statement if one exists), a peptide underwriter typically asks for a specific set of category documents:

• Lab testing documentation, sometimes called a certificate of analysis, for the products actually sold. This is the paperwork that lets a merchant answer a purity dispute with evidence instead of an assurance.
• Supplier agreements or at least a named sourcing chain. Underwriters want to know the product is not being sourced opportunistically from whichever supplier is cheapest that month, since sourcing changes are a common cause of the purity disputes above.
• A full walkthrough of the website, every page a buyer can reach. Underwriters read the actual site copy, not a summary of it, because the label-versus-marketing gap almost always shows up in a specific sentence on a specific page.
• Chargeback ratio history from any prior processor, with an explanation attached. A number alone tells an underwriter nothing about whether the underlying cause was fixed.
• A description of the fulfillment process: who ships, how fast, what the buyer sees for tracking, and what happens when a shipment is delayed, since that is the operational detail behind the biggest dispute category.

None of this is a specific regulatory form or a citation to a specific law. It is the practical documentation set an acquirer wants to see before it takes on the liability of boarding a peptide merchant, and a business that already has these on hand moves through underwriting faster than one that has to assemble them after the fact.

What gets a peptide merchant account shut down fast?

A processor that boards peptide sellers is taking on real reputational and compliance exposure to do it, which means the account is watched closely, and a few things end it quickly.

Affiliate and influencer marketing deserves its own note here, because it is the piece a lot of peptide merchants underestimate. An acquirer that reviews a merchant’s site and finds it clean can still flag the account over a promotional video an affiliate posted, since the processor’s exposure follows the product and the brand, not just the domain it approved. A merchant that pays affiliates or runs an influencer program needs those partners working from the same script the merchant’s own site follows: no dosing for humans, no health outcomes, no before-and-after framing.

None of this is a legal opinion about what peptide sellers may or may not claim, that determination sits with the seller and its own counsel. It is a plain description of what makes an acquirer nervous enough to close an account, because the processor carries liability for what the merchant it boards actually does.

What kind of account actually works for a peptide business?

Most peptide sellers end up with a dedicated high risk account rather than a mainstream aggregator, because an aggregator like Stripe or Square reviews thin files automatically and shuts off access the moment volume or dispute patterns look unusual, often with no real appeal. A dedicated account comes with closer underwriting up front, but the relationship is reviewed by a person who already understands the category, not an automated system that treats every dispute spike the same way.

Expect a reserve and pricing that reflects the category’s real chargeback rate. Read how high risk pricing and reserves work for what that actually looks like on a statement, and payment aggregator vs merchant account for why the aggregator model specifically struggles with this category.

Reserves in this category run higher than in most high risk categories specifically because of the reship and non-delivery dispute volume described above. A rolling reserve, where a percentage of each batch is held for a set number of days before release, is common because it scales automatically with volume and with how disputes actually land weeks after the sale. An upfront reserve, held as a lump sum before processing starts, shows up more often for newer businesses with no processing history to underwrite against. A capped reserve, a fixed ceiling the held amount cannot exceed once it builds up, is the version that eventually gets negotiated once the account has a track record. None of these are unique to peptides, but a peptide file’s reserve terms respond directly to how reliable the fulfillment process is: a business with a tight, documented shipping and refund process gets reviewed for lighter terms sooner than one that cannot show its process is under control.

This is also where what actually makes a business high risk is worth reading, since reserve sizing is one of the clearest places that classification shows up in practice, not just in an application decision.

What should a peptide website look like before applying?

Underwriters read the site before they read anything else, so cleaning it up before applying is the single highest-leverage step a peptide business can take.

• A visible research-use disclaimer, not buried in a footer link, on every product page, not just a general terms page.
• No dosing language written for a person. A dosing calculator, a suggested schedule, or a "how to take" section is the fastest way to contradict the site’s own label.
• No health outcome or performance claims, anywhere on the site, in ad copy, or in email marketing tied to the same domain.
• A refund and return policy visible from the footer, written in plain terms, and actually followed when a customer invokes it.
• Real contact information: an email address or contact form that reaches a person, since a site with no way to reach the merchant reads as a flag on its own.
• No customer testimonials describing personal use or dosing. Even a genuine review becomes evidence against the research-use label the moment it describes taking the product.
• No before-and-after imagery or lifestyle marketing that implies a health or physique outcome. This is the single most common thing an underwriter asks a peptide merchant to remove before approval.

None of this is about hiding what the business sells. It is about making sure the site says one consistent thing about how the product is meant to be used, since the inconsistency between the label and the marketing is what an underwriter is actually screening for.

What if a peptide account was already closed or declined?

If a prior processor closed the account for cause, find out whether a MATCH listing came with it before applying anywhere else. The MATCH list, explained covers how to tell, and merchant account after MATCH covers what changes about the application if a listing is confirmed.

If the account was simply declined with no prior relationship, that is usually a category-level decision rather than anything specific to the business, and it is worth applying with an acquirer that actively works this category rather than reapplying to the same type of processor that declined the first time.

Either way, a business that has been through a shutdown once is a good candidate for a backup merchant account once it is approved again, so a single account closure never takes the business fully offline while a new relationship is found. Read how the application process works for what to expect end to end, or go straight to get in touch to talk through the specific closure with a specialist.